Loading stock data…
$13.74-0.16 (-1.12%)
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia.
Mesoblast Limited in the Healthcare sector is trading at $13.74 with a market capitalization of $1.9B. Wall Street consensus targets $37.00 (2 analysts), implying a +169.3% move over the next 12 months. The stock is currently near its 52-week low of $13.05, remaining 12.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal linea...